Ceres Inc (CERE): Price and Financial Metrics
GET POWR RATINGS... FREE!
CERE Stock Price Chart Interactive Chart >
CERE Price/Volume Stats
|Current price||$34.15||52-week high||$41.46|
|Prev. close||$34.55||52-week low||$19.86|
|Day high||$35.26||Avg. volume||469,396|
|50-day MA||$30.15||Dividend yield||N/A|
|200-day MA||$28.86||Market Cap||5.34B|
Ceres Inc (CERE) Company Bio
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company that combines a deep understanding of the biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) receptor pharmacology to discover and develop new therapies.
Most Popular Stories View All
CERE Latest News Stream
|Loading, please wait...|
CERE Latest Social Stream
View Full CERE Social Stream
Latest CERE News From Around the Web
Below are the latest news stories about CEREVEL THERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate CERE as an investment opportunity.
Cerevel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference and Provide Pipeline Update
Initiated Phase 1 healthy volunteer trial to support development of emraclidine in Alzheimer’s disease psychosis in Q4 2022; second potential indication as a once-daily treatment Phase 2 proof-of-concept darigabat panic disorder trial to be initiated in Q2 2023 Multiple data readouts and cash runway into 2025 to support advancement of diverse pipeline of novel neuroscience drug candidates Cerevel presentation to take place on January 10 at 8:15 a.m. PT/11:15 a.m. ET CAMBRIDGE, Mass., Jan. 09, 20
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference. Dr. Coles will be joined by additional members of the executive team for the question-and-answer portion of the presentation. Date: Tuesday, January 10, 2023 Form
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Cerevel Therapeutics...
Cerevel Therapeutics Announces Positive Results in Emraclidine Ambulatory Blood Pressure Monitoring Trial
Data provide clear evidence that emraclidine does not induce an increase in blood pressure with chronic dosing in people living with schizophrenia Emraclidine demonstrated a mean change from baseline in 24-hour ambulatory systolic blood pressure at week eight of -2.7 mmHg for 10 mg QD and -0.4 mmHg for 30 mg QD Trial ruled out a 3 mmHg or greater increase in 24-hour mean systolic blood pressure for both doses of emraclidine based on the upper bound of the 95% confidence interval, per FDA guidanc
Cerevel Therapeutics Announces Publication in The Lancet of Emraclidine Data from Phase 1b Clinical Trial in People Living with Schizophrenia
Emraclidine is being developed as a potential once-daily treatment for schizophrenia without the need for titration Data show clinically meaningful and statistically significant improvement with emraclidine in PANSS total score at six weeks and was overall well-tolerated compared with placebo Results demonstrate selective targeting of the M4 muscarinic receptor subtype as a potential novel treatment approach for schizophrenia Comprehensive Phase 2 development program in schizophrenia currently u
CERE Price Returns